Companies Dominating the Ocular Drug Delivery Devices Landscape
- Bausch Health Companies Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Taiwan Liposome Company, Ltd.
- Ocular Therapeutix, Inc.
- Kiora Pharmaceuticals, Inc.
- Graybug Vision Inc.
- Apellis Pharmaceuticals, Inc.
- Implanet Company
- Aerie Pharmaceuticals Inc.
- EyePoint Pharmaceuticals, Inc.
- Protalix BioTherapeutics
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of ocular drug delivery devices is estimated at USD 17.82 billion.
The ocular drug delivery devices market size was valued at USD 15.69 billion in 2024 and is set to exceed USD 43.71 billion by 2037, expanding at over 8.2% CAGR during the forecast period i.e., between 2025-2037. Increasing prevalence of ocular diseases and growing awareness amongst people regarding vision impairment will fuel the market growth.
North America industry is poised to dominate majority revenue share by 2037, owing to growing cases of cataracts and diabetes-related visual conditions in the region.
The major players in the market are Bausch Health Companies Inc., Taiwan Liposome Company, Ltd., Ocular Therapeutix, Inc., Kiora Pharmaceuticals, Inc., Graybug Vision Inc., Apellis Pharmaceuticals, Inc., Implanet Company, Aerie Pharmaceuticals Inc., EyePoint Pharmaceuticals, Inc., Protalix BioTherapeutics
